AI Revolutionizes Breast Cancer Diagnosis in Indonesia with First-of-its-Kind Service
Indonesia is poised to significantly improve breast cancer detection and treatment with the launch of the nation’s first AI-based computational pathology service, a collaboration between pharmaceutical giant AstraZeneca and leading hospital group Siloam International Hospitals. The innovative technology promises faster, more precise diagnoses, including the identification of previously challenging sub-categories like HER2-Low and HER2-Ultralow.
Advancing Precision Medicine in Southeast Asia
The initiative, unveiled during Breast Cancer Awareness Month, marks a pivotal moment in healthcare innovation for Indonesia. Computational pathology utilizes artificial intelligence to analyze digitized body tissue, offering a level of accuracy and speed unattainable through traditional methods. This breakthrough is expected to bolster precision medicine efforts, enabling clinicians to tailor treatments to individual patient profiles with greater efficacy.
The collaboration was formalized on October 28, 2025, with signatures from Esra Erkomay, President Director of AstraZeneca Indonesia, and Dr. Grace Frelita Indradjaja, Chief Medical Officer of Siloam Hospitals Group. The AI-powered laboratory service is currently available at Siloam International Hospitals Lippo Village and MRCCC Siloam Hospitals Semanggi, with potential for expansion across the archipelago.
Enhanced Detection Capabilities
A key benefit of the new service lies in its ability to detect nuanced variations in breast cancer, specifically the HER2-Low and HER2-Ultralow subtypes. These categories, historically difficult to identify manually, are now within reach thanks to the analytical power of AI. According to a company release, this enhanced detection capability will lead to more informed treatment decisions and improved patient outcomes.
“With AI technology, the diagnosis process is faster, more accurate and can be accessed in real-time, supporting better clinical decisions for patients,” a senior official stated.
The technology minimizes subjective interpretation, reducing discrepancies between pathologists and accelerating the diagnostic timeline. This speed is crucial in breast cancer care, where early detection is paramount.
A National Health Transformation Agenda
The launch of this AI-driven pathology service aligns directly with the Indonesian Ministry of Health’s national health transformation agenda, which prioritizes increased access to quality healthcare and evidence-based treatments. “Digital transformation is no longer just the future, but a real need,” Dr. Grace Frelita emphasized. “Computational pathology allows every medical decision to be supported by accurate data and comprehensive analysis, so that the quality of health services increases significantly.”
This collaboration represents a significant step forward in empowering Indonesian healthcare professionals with cutting-edge tools and ultimately, offering renewed hope to breast cancer patients throughout the country. The initiative promises a future where faster, more precise, and personalized diagnoses are the standard of care.
